Table 3.

Non-hematologic adverse events by grade

	Decitabine 5-day schedule (n=28)				Decitabine 10-day schedule (n=43)
Parameter	Grade 1–2	Grade 3	Grade 4	Grade 5	Grade 1–2	Grade 3	Grade 4	Grade 5
Acute kidney injury	5 (18)	0	0	0	1 (2)	2 (5)	1 (2)	0
Altered mental status	1 (4)	0	0	0	1 (2)	2 (5)	0	0
Anorexia	0	1 (4)	0	0	2 (5)	0	0	0
Cholecystitis	0	0	0	0	0	1 (2)	0	0
Constipation	2 (7)	0	0	0	0	1 (2)	0	0
Diarrhea	2 (7)	1 (4)	0	0	1 (2)	0	0	0
Dysphagia	0	1 (4)	0	0	0	1 (2)	0	0
Fatigue	3 (11)	2 (7)	0	0	4 (9)	2 (5)	0	0
Febrile neutropenia	0	7 (25)	0	1 (4)	0	12 (28)	2 (5)	0
Hearing loss	0	0	0	0	0	0	1 (2)	0
Hemorrhage	1 (4)	0	1 (4)	1 (4)	0	1 (2)	0	0
Hyperglycemia	0	0	0	0	0	1 (2)	0	0
Hypoglycemia	0	0	0	0	0	1 (2)	0	0
Hyponatremia	0	0	0	0	0	2 (5)	0	0
Hypotension	0	1 (4)	0	0	1 (2)	2 (5)	0	0
Increased bilirubin	1 (4)	1 (4)	0	0	0	0	0	0
Infection	1 (4)	4 (14)	1 (4)	1 (4)	3 (7)	16 (37)	0	6 (14)
Myocardial infarction	0	0	0	0	0	1 (2)	0	0
Nausea	1 (4)	1 (4)	0	0	4 (9)	0	0	0
Pain	1 (4)	1 (4)	0	0	8 (19)	2 (5)	0	0
Pleural effusion	0	2 (7)	0	0	0	0	0	0
Syncope	0	1 (4)	0	0	0	1 (2)	0	0
Transient ischemic attack	0	0	0	0	0	1 (2)	0	0
Venous thromboembolism	0	1 (4)	0	0	1 (2)	0	0	0

Data are n (%). Any grade 1–2 adverse event occuring in ≥10% of patients in either arm, and all grade 3, 4, and 5 adverse events are listed.